Immunovant shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $18 to $55.
Portfolio Pulse from Bill Haddad
Immunovant's stock has been upgraded from Neutral to Buy by UBS, with the price target raised from $18 to $55. This has resulted in Immunovant shares trading higher.
October 13, 2023 | 3:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS has upgraded Immunovant's stock from Neutral to Buy and increased the price target from $18 to $55, leading to a rise in the company's share price.
The upgrade from UBS, a major financial institution, is a strong positive signal for Immunovant. The significant increase in the price target from $18 to $55 indicates a bullish outlook for the company's stock, which is likely to attract investors and drive up the share price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100